Tandem Diabetes Care (TNDM) has wrapped up FY 2025 with Q4 revenue of US$290.4 million and a basic EPS loss of US$0.01, framing a year in which the trailing twelve months show US$1.0 billion of revenue and a basic EPS loss of US$3.04. Over recent quarters, revenue has moved from US$282.6 million in Q4 2024 to US$234.4 million in Q1 2025, then to US$240.7 million in Q2, US$249.3 million in Q3 and back to US$290.4 million in Q4 2025. Quarterly basic EPS has ranged from a small profit of US$0.01 in Q4 2024 to losses of US$1.97, US$0.78, US$0.31 and US$0.01 through FY 2025. For investors, these results highlight a business that is generating substantial revenue but still contending with pressure on margins and the path back to sustained profitability.

See our full analysis for Tandem Diabetes Care.

With the latest figures on the table, the next step is to see how these results line up with the prevailing narratives around Tandem's growth potential, risk profile and timing of a profit recovery.

Losses Narrow Across FY 2025

• Across FY 2025, quarterly net losses moved from US$130.6 million in Q1 to US$52.4 million in Q2, US$21.2 million in Q3 and US$0.6 million in Q4, while trailing 12 month net loss sits at US$204.7 million on about US$1.0 billion of revenue.
• What stands out for the bullish narrative is that this pattern of smaller quarterly losses lines up with the view that profit margins can move from about a 20.2% loss today to a 3.4% profit in roughly three years, even though the trailing 12 month EPS loss of US$3.04 still reflects the pressure from the last few years.
  • Bulls point to catalysts like pharmacy channel expansion and international direct sales to support the forecast that earnings could grow strongly and move into positive territory, and the recent step down in quarterly losses is one concrete data point they highlight.
  • At the same time, the fact that trailing losses have increased at about 39.1% per year over five years is a reminder that the path to those forecast margins is not yet visible in the longer term history, so you are relying more on the future story than on the last few years.

On that point, if you want to see how bullish investors tie these loss numbers to their longer term story, it is worth reading their full case for Tandem in 🐂 Tandem Diabetes Care Bull Case.

Revenue Growth Trails Market Benchmark

• Over the last year, the data show revenue growth of 10.3% per year on a trailing basis compared with a 11.4% per year benchmark for the broader US market, while quarterly revenue has ranged from US$234.4 million in Q1 2025 up to US$290.4 million in Q4 2025.
• Critics in the bearish narrative argue that this kind of growth, slightly below the market benchmark and facing pricing pressure and possible commoditization, may not be enough to offset risks around margins and product obsolescence even if the top line is still growing.
  • Bears highlight that the business is still loss making on about US$1.0 billion of trailing 12 month revenue and that losses have grown over five years, which they see as a sign that revenue growth alone has not yet translated into durable profitability.
  • They also flag the risk that shifts toward new diabetes technologies and potential reimbursement changes could slow revenue growth from the 10.3% level, which would make any future profit recovery more sensitive to cost control and execution.

Skeptical investors who focus on these growth and margin questions often look to a full bear case to see how far those concerns go and what would need to change, which is exactly what you get in 🐻 Tandem Diabetes Care Bear Case.

Low P/S and Large DCF Gap

• The stock trades on a P/S of 1.2x against a peer average of 6.7x and a US Medical Equipment industry average of 2.8x, while a DCF fair value of US$84.56 sits well above the current share price of US$18.47.
• Consensus narrative commentary leans on these metrics as a key part of the upside case, arguing that if earnings grow as forecast and margins improve toward a 3.4% profit in about three years, the wide gap between current valuation multiples and both peers and DCF fair value could narrow.
  • On one hand, the low P/S multiple and the share price trading about 78.2% below the stated DCF fair value are exactly the kind of numbers that valuation focused investors look for when they think the market is pricing in a lot of risk.
  • On the other hand, the same dataset shows that the company remains unprofitable with a trailing 12 month net loss of US$204.7 million and higher share price volatility than the US market, which helps explain why some investors may hesitate to give full credit to those valuation signals yet.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tandem Diabetes Care on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals on growth, margins and valuation, the real question is how you weigh the trade off between the risks and the potential rewards. For more detail, take a closer look at the full risk and reward breakdown in 3 key rewards and 1 important warning sign

See What Else Is Out There

Tandem is still loss making on about US$1.0b of revenue, with growing historical losses and higher share price volatility adding to the risk profile.

If this mix of ongoing losses and volatility feels uncomfortable, you can instantly narrow the field to companies with steadier profiles by checking out 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.